Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Zeria Pharmaceutical Employee's Death Was 'Job-Related' August 8, 2017 Massachusetts' Agenus Quietly Discloses Failure of Cancer Vaccine Trial February 21, 2017 GeoVax Labs Inc. Awarded NIH Grant For Zika Vaccine June 18, 2017
